Akebia Therapeutics(AKBA) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights Corporate Updates • Vafseo (vadadustat) Tablets market availability on track for January 2025 ® • TDAPA application submission and WAC pricing announcement for Vafseo complete • Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 million • In June, Akebia submitted its Transitional Drug Add-on Payment Adjustment (TDAPA) application. Akebia expects to have Healthcare Common Pr ...